Get the Stockscreener App
6.735
4.87%
-0.345
After Hours:
6.64
-0.095
-1.41%
Karyopharm Therapeutics Inc stock is traded at $6.735, with a volume of 52,712.
It is down -4.87% in the last 24 hours and up +67.54% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$7.08
Open:
$7.12
24h Volume:
52,712
Relative Volume:
0.35
Market Cap:
$58.40M
Revenue:
$137.27M
Net Income/Loss:
$-123.57M
P/E Ratio:
-0.6151
EPS:
-10.95
Net Cash Flow:
$-102.89M
1W Performance:
-12.30%
1M Performance:
+67.54%
6M Performance:
+5.73%
1Y Performance:
-37.00%
1-Day Range:
$6.70
$7.17
1-Week Range:
$6.6386
$7.721
52-Week Range:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.735 | 58.79M | 137.27M | -123.57M | -102.89M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Is Karyopharm Therapeutics Inc. gaining market shareCEO Change & Scalable Portfolio Growth Methods - khodrobank.com
Can Karyopharm Therapeutics Inc. recover in the next quarterInsider Buying & Real-Time Buy Signal Notifications - Newser
Analyzing recovery setups for Karyopharm Therapeutics Inc. investorsJuly 2025 Outlook & Technical Pattern Based Buy Signals - Newser
Published on: 2025-09-03 09:05:10 - Newser
Strategies to average down on Karyopharm Therapeutics Inc.July 2025 Earnings & Safe Swing Trade Setups - Newser
Will Karyopharm Therapeutics Inc. benefit from rate cutsJuly 2025 News Drivers & Comprehensive Market Scan Reports - khodrobank.com
What machine learning models say about Karyopharm Therapeutics Inc.Trade Exit Summary & Weekly High Potential Alerts - Newser
Is now the right time to enter Karyopharm Therapeutics Inc.Weekly Risk Report & Fast Gain Swing Alerts - khodrobank.com
How to use a screener to detect Karyopharm Therapeutics Inc. breakoutsStock Surge & Free Technical Confirmation Trade Alerts - Newser
Karyopharm Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Using data tools to time your Karyopharm Therapeutics Inc. exitForecast Cut & Stock Market Timing Techniques - Newser
Is Karyopharm Therapeutics Inc. benefiting from innovation trends2025 Volatility Report & Capital Protection Trading Alerts - خودرو بانک
What candlestick patterns are forming on Karyopharm Therapeutics Inc.Market Rally & AI Enhanced Execution Alerts - Newser
Karyopharm Therapeutics Inc. stock daily chart insightsQuarterly Market Review & Accurate Buy Signal Notifications - Newser
What high frequency data says about Karyopharm Therapeutics Inc.Weekly Stock Recap & Accurate Entry/Exit Alerts - Newser
Can you recover from losses in Karyopharm Therapeutics Inc.July 2025 EndofMonth & Accurate Entry/Exit Alerts - Newser
What are Karyopharm Therapeutics Inc.’s recent SEC filings showingPortfolio Growth Summary & Risk Adjusted Swing Trade Ideas - خودرو بانک
Analyzing Karyopharm Therapeutics Inc. with multi timeframe chartsQuarterly Growth Report & Accurate Trade Setup Notifications - Newser
How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesBull Run & Real-Time Volume Spike Alerts - Newser
Published on: 2025-09-01 11:39:57 - beatles.ru
What momentum shifts mean for Karyopharm Therapeutics Inc.2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
Forecasting Karyopharm Therapeutics Inc. price range with options dataMarket Volume Report & High Accuracy Trade Signal Alerts - Newser
How to read the order book for Karyopharm Therapeutics Inc.Market Sentiment Report & Reliable Price Action Trade Plans - Newser
Will Karyopharm Therapeutics Inc. stock go up soon2025 Risk Factors & Low Risk High Reward Ideas - Newser
Can Karyopharm Therapeutics Inc. hit a new high this monthChart Signals & High Win Rate Trade Alerts - Newser
Trend analysis for Karyopharm Therapeutics Inc. this weekJuly 2025 Catalysts & Weekly Breakout Stock Alerts - Newser
Multi factor analysis applied to Karyopharm Therapeutics Inc.July 2025 Drop Watch & Daily Stock Trend Reports - Newser
Using AI based signals to follow Karyopharm Therapeutics Inc.Dividend Hike & Expert Approved Momentum Trade Ideas - Newser
Karyopharm Therapeutics Inc. stock prediction for this weekTrade Volume Report & Advanced Swing Trade Entry Plans - Newser
Is Karyopharm Therapeutics Inc. trending in predictive chart modelsPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Is a relief rally coming for Karyopharm Therapeutics Inc. holdersPortfolio Risk Report & Safe Entry Trade Signal Reports - Newser
Using flow based indicators on Karyopharm Therapeutics Inc.July 2025 Rallies & Safe Capital Allocation Plans - Newser
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Karyopharm Therapeutics Inc Stock (KPTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Abate Kristin | Chief Accounting Officer |
Jul 22 '25 |
Sale |
4.00 |
238 |
952 |
9,475 |
| Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 23 '25 |
Sale |
6.17 |
419 |
2,585 |
28,853 |
| Paulson Richard A. | President and CEO |
Apr 04 '25 |
Sale |
3.74 |
245 |
916 |
82,739 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Mar 04 '25 |
Sale |
6.29 |
3,445 |
21,669 |
34,314 |
| Paulson Richard A. | President and CEO |
Mar 04 '25 |
Sale |
6.29 |
11,694 |
73,555 |
82,984 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 04 '25 |
Sale |
6.29 |
3,587 |
22,562 |
29,272 |
| Poulton Stuart | EVP, Chief Development Officer |
Mar 04 '25 |
Sale |
6.29 |
3,548 |
22,317 |
27,414 |
| Mano Michael | SVP, General Counsel&Secretary |
Mar 04 '25 |
Sale |
6.29 |
2,793 |
17,568 |
21,047 |
| Poulton Stuart | EVP, Chief Development Officer |
Feb 18 '25 |
Sale |
0.63 |
5,914 |
3,726 |
320,714 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):